What kind of medicine is Inalisate and its applicable disease types?

Inavolisib (Inavolisib) is a new type of small molecule targeted drug, which is a PI3Kα selective inhibitor. It exerts anti-tumor effects by inhibiting the abnormal activation of phosphatidylinositol 3-kinase (PI3K) signaling pathway, inhibiting the proliferation and survival of tumor cells. Compared with traditional chemotherapy drugs, inaliside has the characteristics of strong targeting and relatively controllable side effects, so it has received widespread attention in the field of precision treatment.

In terms of indications, inalise is mainly used for patients with advanced breast cancer related to PIK3CA gene mutations. PIK3CAGene mutations are relatively common in breast cancer, especially in patients with hormone receptor-positive (HR+) and HER2-negative types. For this type of gene mutation, inalise can effectively inhibit tumor growth signals, delay disease progression, and improve treatment response rates, providing patients with a new targeted treatment option.

Clinical studies have shown that inaliset can significantly prolong progression-free survival (PFS) when combined with endocrine therapy (such as fulvestrant, letrozole, etc.), especially for advanced patients who have received multiple lines of endocrine therapy, it can still achieve good clinical efficacy. This shows that inaliset not only has potential in newly treated patients, but is also suitable for relapsed or drug-resistant patients, providing more clinical treatment strategies.

In addition, the dosage regimen and safety characteristics of inaliset also deserve attention. As a targeted drug, patients need to regularly monitor blood sugar, blood lipids, liver function and other indicators during use in order to promptly detect and deal with possible adverse reactions, such as hyperglycemia, rash or mild to moderate gastrointestinal reactions. Overall, inalise represents a precise anti-cancer strategy targeting the PI3K signaling pathway, which has important clinical value in the treatment of breast cancer and provides a new direction for the development of gene mutation-targeted therapy.

Reference link:https://www.drugs.com